Compounding pharmacies keep copying Zepbound despite FDA ban
The FDA has yet to comment on how it will proceed. Eli Lilly could pursue legal action against compounding pharmacies.
GLP-1s
Olio Labs study shows why women experience more GLP-1 side effects
With the obesity treatment market expected to reach $200 billion by 2031, this study could greatly influence future therapeutic approaches.
Novo Nordisk: FDA confirms end of Wegovy and Ozempic shortage
Novo Nordisk has increased manufacturing, running production facilities 24/7 to ensure steady shipments to wholesalers.
